Three-dimensional fibroblast aggregate and in vitro three-dimensional skin dermis model containing the same

By coating the binding active protein in the culture container, fibroblasts form a three-dimensional aggregate, and an in vitro three-dimensional skin dermis model is created, which solves the problems of low drug screening efficiency and slow biodegradation speed in the prior art, and achieves high efficiency, Accurate drug screening and simulate skin environments.

CN113583946BActive Publication Date: 2024-11-08S-BIOMEDICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110909867.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2015-11-12
Filing Date
2016-04-19
Publication Date
2024-11-08
Estimated Expiration
2036-04-19

AI Technical Summary

Technical Problem

The existing technology is difficult to quickly screen drugs, especially under the conditions of skin environment simulation, and the two-dimensional cell model cannot accurately predict the response to the skin, and the existing artificial skin has problems with the speed of biodecomposition and inflammatory response, which limits its commercial use. change.

Method used

By coating proteins with binding activity in culture containers, fibroblasts form a three-dimensional cell aggregate, this method is used to create an in vitro three-dimensional skin dermal model, and use this model to screen substances that reduce or increase MMP expression or activity.

Benefits of technology

The formation of three-dimensional fibroblasts aggregates without artificial three-dimensional porous extracellular matrix is ​​achieved, which simulates the structure and function of the skin, improves the efficiency and accuracy of drug screening, and reduces the risk of biodegradation and inflammatory response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113583946B_ABST
    Figure CN113583946B_ABST
Patent Text Reader

Abstract

The present invention provides a three-dimensional fibroblast aggregate, a method for producing the cell aggregate, an in vitro three-dimensional skin dermis model comprising the fibroblast aggregate cultured from fibroblasts, and a method for screening drugs using the model.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an invention patent application with an application date of April 19, 2016, application number 201680003627.X, and invention name "Three-dimensional fibroblast aggregate and in vitro three-dimensional skin dermis model containing the same". Technical Field

[0002] The present invention relates to a three-dimensional fibroblast cell aggregate, a method for producing the cell aggregate, an in vitro three-dimensional skin dermis model containing the cell aggregate, and a method for screening drugs using the cell aggregate. Background Art

[0003] Recently, cell therapy technology has attracted attention as a new field for the treatment of intractable diseases, etc. To date, organ transplantation and gene therapy have been proposed to treat intractable diseases in humans, but due to immune rejection, insufficient organ supply, insufficient vector development, or insufficient knowledge about disease genes, effective practical application has not been achieved.

[0004] As a result, there is a growing interest in cell therapy technology, and the technology of proliferating and transplanting cells isolated from a living body outside a living body is being commercialized, and the practical application of artificial skin, cartilage or fibrous tissue reconstruction is continuing. Fibroblasts are cells used to produce and maintain interstitial extracellular matrix (ECM), and fibroblasts are organically connected through the extracellular matrix. In addition, fibroblasts are widely known as cells that produce various cytokines and physiologically active factors for immune defense.

[0005] In order to flexibly utilize such fibroblasts as cell therapy agents or tissue engineering materials, fibroblasts are cultured in a two-dimensional manner and proliferated in large quantities, and then treated with enzymes such as trypsin. However, in such fibroblasts, the role of the extracellular matrix cannot be expected in the step of decomposing and transplanting the generated extracellular matrix. As a tissue engineering technology, research has been conducted on culturing various cells including fibroblasts into three-dimensional cell aggregates using biodegradable synthetic polymers or natural polymers and artificial three-dimensional porous extracellular matrices called scaffolds. However, there are limitations on materials such as biodegradation speed or inflammatory response, making it difficult to commercialize, so a technology for inducing the formation of three-dimensional cell aggregates is needed.

[0006] On the other hand, the skin tissue of the human body is generally divided into three parts, namely, the outermost epidermis forming the skin, the dermis below it, and the subcutaneous tissue. Among them, the epidermis is composed of epithelial cells differentiated from the basement membrane (basement membrane) used to firmly combine the epidermis and the dermis into multiple layers, as well as melanocytes and immune cells outside the epidermis. The dermis below the epidermis is mainly composed of fibroblasts and various extracellular matrices (extracellular matrix) secreted by the cells. It is well known that the dermis is closely related to skin health and aging.

[0007] Collagen is the main protein that occupies 90% of the dermis and is used to maintain the skin's binding tissue and provide skin elasticity. Generally, with the increase of external factors and age, the number and function of fibroblasts decrease, which is known to be the main cause of aging. The reduction of cells triggers the synthesis of fibrous components in skin tissue and the loss of water, as well as changes in the stratum corneum. In addition, the increase of collagenase reduces the cross-linked collagen, which reduces the smoothness, moisture and elasticity of the skin. The increase in collagen content and synthesis means an increase in moisture and elasticity of the skin.

[0008] The decomposition and synthesis of collagen in the skin matrix are regulated by matrix metalloproteinases (MMPs) which are proteases. MMPs are divided into multiple categories based on their structural and functional properties. Type I collagen, a typical collagen of the skin, is decomposed by the action of MMP-1. MMP-1 activity is regulated by inhibitors such as TIMP-1, which is secreted to maintain the homeostasis of the skin. Biomolecules such as MMPs and TIMPs are secreted by cells including fibroblasts. Moreover, MMP-1 decomposes the extracellular matrix and thereby promotes tumor metastasis and progression. Collagen synthesis and decomposition based on MMP-1 play an important role in the metastasis of cancer. Therefore, drugs and substances targeting MMP-1 / collagen are developed for the purpose of cancer therapeutic agents or cosmetic compositions.

[0009] Furthermore, it is known that MMPs are overexpressed in pathological conditions such as inflammatory diseases such as arthritis or cancers such as cancer metastasis, and MMP inhibitors targeting MMPs are being developed as therapeutic agents for such diseases.

[0010] As described above, the 2D cell-based test for screening drugs targeting MMP or collagen has limitations due to drug sensitivity and drug penetration into cells and tissues, and is not suitable for accurately predicting the response of living organisms. In addition, due to the complexity of the structure and function of the skin, skin research using one type of skin cell has limitations. The three-dimensional skin model developed to overcome this is artificial skin, but existing artificial skin has the limitation of being difficult to screen drugs at high speed. Therefore, if you want to screen drugs quickly (high-throughput), you need to develop a new skin model system that can be used for skin environment simulation. Summary of the invention

[0011] Technical issues

[0012] One form of the present invention is to provide a method for producing fibroblast clusters, comprising the following steps: culturing fibroblasts in a liquid culture medium in a culture container to obtain a culture containing fibroblast clusters formed by detachment of fibroblasts from a surface, wherein the culture container has a surface coated with a protein, and the protein has an activity of binding to fibroblasts; and separating the fibroblast clusters from the culture, wherein the protein having an activity of binding to the fibroblasts binds to the fibroblasts in a manner weaker than the binding between fibroblasts.

[0013] Another aspect of the present invention is to provide a fibroblast aggregate produced by the above method.

[0014] Another aspect of the present invention is to provide an in vitro three-dimensional skin dermis model including a fibroblast aggregate cultured from fibroblasts.

[0015] Another aspect of the present invention is to provide a method for manufacturing an in vitro three-dimensional artificial skin model, comprising the following steps: culturing fibroblasts in a liquid culture medium in a culture container to obtain a culture containing fibroblast clusters formed by detachment of fibroblasts from a surface, wherein the culture container has a surface coated with a protein, the protein has an activity of binding to fibroblasts, and the protein having the activity of binding to fibroblasts binds to the fibroblasts in a manner weaker than the binding between fibroblasts; and culturing the fibroblast clusters derived from the culture for at least 12 hours.

[0016] Other forms of the present invention are intended to provide a method for screening substances that reduce the expression or activity of MMP, comprising the following steps: treating the fibroblast aggregate or in vitro three-dimensional skin dermis model with a test substance; measuring the expression or activity level of MMP in the fibroblast aggregate or skin dermis model treated with the test substance; comparing the measured expression or activity level of MMP with that of an untreated control group; and screening substances that reduce the expression or activity of MMP relative to the control group.

[0017] Another different form of the present invention is to provide a method for screening substances that increase the expression or activity of collagen, comprising the following steps: treating the fibroblast aggregate or in vitro three-dimensional skin dermis model with the substance to be tested; measuring the level of collagen expression or activity in the fibroblast aggregate or skin dermis model treated with the substance to be tested; comparing the measured level of collagen expression or activity with that of an untreated control group; and screening substances that increase the expression or activity of collagen relative to the control group.

[0018] Technical Solution

[0019] According to one aspect of the present invention, there is provided a method for producing fibroblast clusters, comprising the following steps: culturing fibroblasts in a liquid culture medium in a culture container to obtain a culture containing fibroblast clusters formed by detachment of fibroblasts from a surface, wherein the culture container has a surface coated with a protein having an activity of binding to fibroblasts; and separating the fibroblast clusters from the culture, wherein the protein having an activity of binding to the fibroblasts binds to the fibroblasts in a manner weaker than the binding between fibroblasts.

[0020] According to another aspect of the present invention, there is provided a culture container for forming a fibroblast aggregate, which is constructed as follows: fibroblasts adhere to the surface of the culture container in a culture medium, and the surface is coated with a protein having an activity of binding to the fibroblasts, wherein the protein having an activity of binding to the fibroblasts binds to the fibroblasts in a manner weaker than the binding between fibroblasts.

[0021] In the present invention, the term "fibroblast" (used interchangeably with "fiber cell") is a cell used to constitute a component of fibrous connective tissue, and can refer to cells of connective tissue of mammals. Fibroblasts can be used to produce extracellular matrix and collagen, and can play a role in healing wounds, such as for treating scars, burns, bedsores or wounds of the skin.

[0022] The term "fibroblast cluster" or "three-dimensional fibroblast cluster" (interchangeably used with "fibroblast tissue") refers to a state in which more than two cells are densely packed, and can be either a tissue state or a single cell state. Each cell cluster can exist as a tissue itself or a part, or a cluster of single cells, and can include fibroblast-like tissues. Moreover, the term "three-dimensional" can refer to a non-two-dimensional solid with a geometric model of three parameters (such as depth, width, height or X, Y, Z axes), so according to a specific example, a fibroblast cluster can refer to the following fibroblast cluster: it is cultured in three dimensions, that is, it is detached from the culture container and cultured in a floating state, so that as the cells proliferate, it has a three-dimensional spherical, sheet-like or similar three-dimensional morphology (for example, similar to a tissue). Furthermore, for a fibroblast aggregate according to a specific example, there is no need to use an artificial three-dimensional porous extracellular matrix through tissue engineering technology, for example, there is no need to use a biodegradable synthetic polymer or natural polymer support such as a sheet, hydrogel, membrane, or scaffold, which means that a three-dimensional fibroblast aggregate can be formed by itself. The tissue engineering technology is not a cell, but a three-dimensional matrix, which is different from the three-dimensional fibroblast aggregate according to a specific example.

[0023] The seeding of fibroblasts into the culture container may include all actions performed to culture fibroblasts in the culture container, including: adding fibroblasts to the culture container; or adhering fibroblasts to the culture container.

[0024] The term "cell adhesion or cell binding" may include: adhesion or binding between cells; and adhesion or binding between cells and the surface of a culture container or biological material. The adhesion or binding of cells on the surface of a culture container or biological material may have various mechanisms. For example, it includes: specific cell adhesion mediated by biological recognition; and nonspecific cell adhesion dominated by static electricity or surface energy. Specific cell adhesion may refer to the following adhesion: specific peptides (e.g., arginine-glycine-aspartidacid; RGD) present in collagen, fibronectin, laminin, etc., which are proteins of the extracellular matrix (ECM), are bound by means of aqueous solutions present in the cell membrane, thereby inducing adhesion. Nonspecific cell adhesion may refer to the following adhesion: the surface to which the cell membrane having negatively charged phospholipids adheres is made positively charged, thereby inducing cell adhesion.

[0025] The culture container may include a hydrophobic surface, for example, a surface with a water contact angle of 90 to 150°, and may be a surface on which a protein having an activity of adhering or binding to fibroblasts is coated. The culture container having a modified surface may include a surface induced in the following manner: the binding between the cell and the adhesion matrix (for example, a protein or growth factor having an activity of binding to the cells coated on the surface of the culture container) is weaker than the binding between cells. The fibroblasts are adhesion-dependent cells such as epithelial cells or mesenchymal cells that grow by adhering to the extracellular matrix, which are different from blood cells. If the cells do not adhere to the adhesion matrix, cell death is induced, and this cell death is called ANOKIS. For the culture method according to a specific example, cell death is not induced in the adhesion or binding between the cell and the adhesion matrix, and the adhesion or binding between the cell and the adhesion matrix is ​​induced in a manner weaker than the adhesion or binding between the cell and the cell, so that it will not be cultured into a two-dimensional monolayer. That is, the fibroblasts are induced to have weaker cell-adhesion matrix adhesion or binding at the initial stage of culture, and because the cell-cell adhesion or binding is induced, a two-dimensional fibroblast aggregate is formed with the help of such cell binding, and as the culture time increases, the two-dimensional fibroblast aggregate detaches or separates from the surface of the culture container, and the detached or separated two-dimensional fibroblast aggregate continues to be cultured in the culture container in a floating state, thereby forming a three-dimensional fibroblast aggregate.

[0026] In order to induce adhesion or binding between a cell and an adhesion matrix (e.g., a protein or growth factor having an activity of binding to cells coated on the surface of a culture vessel) more weakly than the adhesion or binding between the cells, the surface of the culture vessel can be modified by inducing the adhesion or binding using a protein having an activity of binding to fibroblasts.

[0027] When using proteins (e.g., collagen, fibronectin, laminin, etc.) that bind to integrins present in the cell membrane of fibroblasts, the adhesion or binding between the cell-adhesion matrix is ​​strongly induced. The term "integrin" may represent a water-soluble molecule that exists in the cell membrane and acts when the cell adheres to an extracellular matrix such as fibronectin and collagen, and as a membrane-penetrating glycoprotein composed of two small units of α or β, it may include all types of integrins. Therefore, the protein having the activity of binding to the fibroblasts may be weaker than the strength of the fibroblasts binding to fibronectin in the culture medium. In addition, the protein having the activity of binding to the fibroblasts binds to the fibroblasts in the culture medium with an activity of 60 to 95% compared to the strength of the fibroblasts binding to fibronectin, for example, 60, 70, 80, 90 or 95%. Therefore, the protein having the activity of binding to the fibroblasts may include a protein that does not bind to integrins. Moreover, in one specific example, the protein that does not bind to integrin may include a protein that binds to heparan sulfate proteoglycan present in the cell membrane of fibroblasts. In one specific example, the protein that binds to the heparan sulfate proteoglycan may be fibroblast growth factor (FGF). Furthermore, the protein may be a protein that is fixed to the surface of a culture container at a concentration of 5 to 100 μg / ml.

[0028] The term "fibroblast growth factor (FGF)" as a type of growth factor can refer to a growth factor that induces proliferation by stimulating fibroblasts. As a heparin-binding protein, fibroblast growth factor can interact with heparan sulfate proteoglycan of fibroblasts as described above. FGF may include 22 types, for example, may include: FGF 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22. Even if the names of the types are different, as long as those skilled in the art can recognize that they mean the same protein, they can all be included in the types of FGF. For example, FGF 11, 12, 13 and 14 are also known as "iFGF", and FGF 15 is also known as "FGF 15 / 19". Furthermore, for example, FGF 1 or FGF 2 may include "heparin-binding growth factor 1 (HBGF-1)" or "heparin-binding growth factor 2 (HBGF-2)".

[0029] The immobilization of the protein having the activity of binding to the fibroblasts on the surface of the culture container is used to fix the polypeptide on the surface of the solid matrix, which can be achieved by all methods known in the relevant technical field, such as physical adsorption, covalent bonds based on non-selective chemical reactions, etc. As examples of such immobilization methods, the following methods can be included: after binding the protein to biotin, the protein is applied to a solid surface treated with streptavidin or avidin, thereby immobilizing the protein by biotin-streptavidin / avidin binding; using plasma to gather active groups (chemical reaction groups for fixing proteins based on chemical bonds) on the substrate, thereby fixing the protein; using a sol-gel method to form a specific surface area on the surface of a solid substrate. A porous sol-gel film is sufficiently increased, and then the protein is fixed to the porous film by physical adsorption; the anti-thrombotic protein is fixed to the surface of polytetrafluoroethylene (PTFE) by plasma reaction; the cationic amino acid residues are continuously fused to two or more enzymes in two enzymes to combine them, thereby fixing the protein; using a matrix to fix the protein to a hydrophobic polymer layer combined with a solid support platform; using a buffer component to fix the protein on a plastic surface; in an alcohol solution, the protein is brought into contact with a solid surface with a hydrophobic surface to fix the protein.

[0030] Furthermore, a polypeptide chain (link) that can be expressed in large quantities and easily purified in terms of recombinant expression can be used to perform immobilization in the form of a polypeptide chain-growth factor (e.g., FGF) recombinant protein in which the amino acid terminal of a growth factor (e.g., FGF) is fused to the carboxyl terminal of the polypeptide chain. The growth factor is immobilized on a hydrophobic surface in the form of a recombinant protein while maintaining the original biological activity of the growth factor using the polypeptide chain, and then the fibroblasts are adhered to the surface using the adhesion activity of the fibroblasts to the immobilized growth factor, thereby achieving efficient culturing of the fibroblasts.

[0031] The polypeptide chain suitable for the present invention binds to the amino terminal of the growth factor through its carboxyl terminal and can be adsorbed to a culture container having a hydrophobic surface through the hydrophobic region present at the amino terminal. Any polypeptide chain can be used as long as it can achieve large-scale expression and easy purification in terms of recombinant expression and does not affect the culture of fibroblasts. Examples of the polypeptide chain include maltose-binding protein (MBP), hydrophobin, hydrophobic cell penetrating peptides (CPPs), etc.

[0032] MBP (NCBI GenBank Accession No. AAB59056) can represent the following membrane peripheral (periplasm) protein: it crosses the cell membrane of Escherichia coli and is located in the protoplasmic membrane space, and is involved in the movement of sugars such as maltose or maltodextrin into the cell. MBP is mainly used to produce useful foreign proteins in the form of recombinant proteins. It is produced by decoding from the gene malE in the cell, and when the gene of the foreign protein is inserted downstream of the cloned malE gene and expressed in the cell, the recombinant protein bound by the two proteins can be easily produced in large quantities. In particular, when the size of the protein to be expressed is small or it is a foreign protein with reduced stability in other host cells, it may be advantageous to express it in the cell in the form of a recombinant protein using MBP as described above. In this way, the foreign protein expressed by the gene bound to the malE gene can be separated by using the property that MBP has a binding affinity with maltose. For example, by reacting a resin coated with amylose in a maltose-multiplexed form with a cell lysate, washing the reacted resin several times to remove other contaminating proteins, and then adding a high concentration of maltose to compete, the desired protein can be easily eluted alone.

[0033] The MBP-cell adhesion matrix (such as growth factor) recombinant protein can be manufactured by chemical synthesis or gene recombination technology commonly used in the industry, and the transformed bacteria for expressing the trait can be cultured under appropriate conditions, and then the recombinant protein can be recovered from the culture fluid to obtain it. The process of fixing the MBP-cell adhesion matrix recombinant protein obtained in this way to a culture container with a hydrophobic surface does not require special treatment, but can be spontaneously achieved by utilizing the hydrophobic region located at the amino terminal of the recombinant protein polypeptide chain and by means of physical adsorption between the hydrophobic surface and the recombinant protein.

[0034] Furthermore, a method for inducing adhesion or binding between cells and an adhesion matrix (e.g., a protein having an activity of binding to fibroblasts) to be weaker than the adhesion or binding between the cells may be a method for inducing adhesion or binding between fibroblasts and a matrix (e.g., the surface of a culture container) by treating the cells with a substance that weakens the adhesion or binding between the fibroblasts and the matrix (e.g., the surface of a culture container).

[0035] The culture container having a hydrophobic surface, for example, a culture container having a surface with a water contact angle of 90 to 150°, can be a cell culture container made of a polymer that imparts hydrophobicity to a conventional cell culture container, or can be a cell culture container made of such a polymer. Such hydrophobic polymers include, but are not limited to, polystyrene, polymethyl methacrylate (PMMA), polyethylene terephthalate (PET), polyvinyl chloride (PVC), polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), poly(L-lactic acid) (PLLA), poly(D,L-lactic acid) (PDLLA), poly(glycolic acid) (PGA), poly(caprolactone) (PCL), poly(hydroxyalkanoate), polydioxanone (PDS), polytrimethylene carbonate, or copolylactic acid-glycolic acid copolymer (PLGA), poly(L-lactide-co-caprolactone) (PLCL), poly(glycolic acid-co-caprolactone) (PGCL), and derivatives thereof. Furthermore, according to a specific example, a suitable culture container may have a surface comprising a hydrophobic silanized surface, a carbon nanotube (CNT) surface, a hydrocarbon coated surface, or a metal (e.g., stainless steel, titanium, gold, platinum, etc.) surface.

[0036] Before the fibroblasts are seeded into a culture container, the fibroblasts may be cultured cells that have been subcultured. The subculture method may be a method in which fibroblasts separated by a known method are subcultured by a known method. For example, for the separated fibroblasts, cells that have been cultured for 1 passage may be directly used in the subsequent formation of a three-dimensional fibroblast aggregate, or cells that have been cultured for 10 passages or more may be used.

[0037] The fibroblasts can be seeded at a concentration of 1.0×10 4 Up to 2.0×10 5 Cells / cm 2 For example, the cell concentration may be 7.5 × 10 4 to 1.5×10 5 Cells / cm 2 or 1.25 × 10 5 Cells / cm 2 If the cell concentration is 1.0×10 4 If the cell size is 1.25×10 5 Cells / cm 2 In the above manner, a three-dimensional cell aggregate of a size that can be recognized by the naked eye can be formed.

[0038] The culture period may be 1 day to 1 week. The culture medium suitable for the culture is a culture medium generally used for the culture and / or differentiation of fibroblasts, and any medium containing serum or serum-free may be used without limitation, for example, DMEM (Dulbeco's modified eagle medium), Ham's F12, a mixture thereof, or a medium supplemented with serum may be used.

[0039] As described above, in the step of fibroblasts forming three-dimensional fibroblast aggregates, the two-dimensional fibroblast aggregates formed in the early stage are detached from the surface of the culture container by means of the bonding between the cells and the adhesion matrix, and the detached two-dimensional fibroblast aggregates continue to be cultured in the culture container in a floating state, thereby forming a three-dimensional cell aggregate.

[0040] The fibroblast aggregate formed by culturing the fibroblasts on the surface of the culture container by adhering them has a diameter that can be detected by the naked eye, so it can be separated using a pipette, or can be easily obtained by filtering or centrifuging. That is, the step of obtaining the fibroblast aggregate formed by the culture container can be achieved by enzyme-free treatment. The three-dimensional cell aggregate thus obtained can be used as follows: enzymatic treatment using collagenase, trypsin or neutral protease (dispase), mechanical treatment using pressure, or a combination of these treatments to disintegrate the aggregate morphology and use it in the form of a single cell, or directly use it in the form of a three-dimensional cell aggregate.

[0041] As another aspect, a fibroblast mass produced by the above method is provided.

[0042] The method for producing the fibroblast aggregate is the same as described above.

[0043] The fibroblast aggregate may be a sphere or sheet of a size that can be recognized by the naked eye, for example, a spherical fibroblast aggregate with a diameter of 300 to 2000 μm, and in a specific example, 300 to 1000 μm. The diameter of the spherical fibroblast aggregate can be adjusted to a size that can be recognized by the naked eye by a culture method according to a specific example. Moreover, the spherical fibroblast aggregate according to a specific example can include 3.0×10 5 to 1.0×10 6 In another embodiment, the fibroblast aggregate can secrete epithelial growth factor (EGF), extracellular matrix (ECM) or vascular endothelial growth factor (VEGF).

[0044] Therefore, the fibroblast cell mass according to one specific example can be effectively used as a cell source for supplying a cell therapy agent or a physiologically active substance. The use of the fibroblast cell mass will be described below.

[0045] According to another aspect, a cell therapy agent for skin regeneration or angiogenesis is provided, comprising a fibroblast aggregate according to one embodiment.

[0046] Furthermore, a pharmaceutical composition for preventing and treating skin scars, burns, bedsores or ischemic diseases is provided, which contains the fibroblast aggregate according to one specific example or a culture solution thereof as an active ingredient.

[0047] As described above, the fibroblast aggregate can secrete epithelial cell growth factor, extracellular matrix or vascular endothelial growth factor, so it can be transplanted to an individual in need thereof to perform a role as a cell source, thereby promoting skin regeneration or angiogenesis. In addition, by promoting skin regeneration or angiogenesis, it can also be effectively used in a pharmaceutical composition for the prevention and treatment of skin scars, burns, bedsores or ischemic diseases. The ischemic disease can be, for example, ischemic heart disease, ischemic myocardial infarction, ischemic heart failure, ischemic enteritis, ischemic vascular disease, ischemic eye disease, ischemic retinopathy, ischemic glaucoma, ischemic renal failure, ischemic alopecia, ischemic stroke and ischemic lower limb disease.

[0048] According to one specific example, the dosage of the cell therapy agent or pharmaceutical composition is based on the fibroblast cell mass constituting the cell mass as the active ingredient, and can be 1.0×10 5 to 1.0×10 8 cells / kg (body weight) or 1.0×10 7 to 1.0×10 8 Cells / kg (body weight). However, the dosage is variously adjusted due to factors such as formulation method, administration method, patient's age, body weight, sex, pathological state, diet, administration time, administration route, excretion rate and reaction sensitivity. As long as the technicians in this field can appropriately adjust the dosage by considering such factors. The number of administrations can be 1 time or more than 2 times within the scope of clinically allowable side effects. Regarding the administration site, it can be administered to 1 or more than 2 places. For animals other than humans, per kg is administered with the same amount as humans, or, for example, the dosage is converted to a converted amount by the volume ratio (such as the average value) of the organ (heart, etc.) between the target animal and humans. As the target animal for treatment according to a specific example, humans and mammals other than humans as the purpose can be included, for example, including humans, monkeys, mice, rats, rabbits, sheep, cattle, dogs, horses, pigs, etc.

[0049] According to a specific example of a cell therapy agent or pharmaceutical composition, as an effective ingredient, a cell aggregate and a pharmaceutically acceptable carrier and / or additive may be included. For example, sterile water, physiological saline, conventional buffers (phosphoric acid, citric acid, other organic acids, etc.), stabilizers, salts, antioxidants (ascorbic acid, etc.), surfactants, suspending agents, isotonic agents or preservatives, etc. may be included. For local administration, it is preferably combined with organic substances such as biopolymers, inorganic substances such as hydroxyapatite, specifically with collagen matrix, polylactic acid polymers or copolymers, polyglycol polymers or copolymers and chemical derivatives thereof. When a cell therapy agent or pharmaceutical composition according to a specific example is manufactured into a dosage form suitable for injection, the cell aggregate can be dissolved in a pharmaceutically acceptable carrier, or frozen in a dissolved solution state.

[0050] According to a specific example, the cell therapy agent or pharmaceutical composition may appropriately include a suspending agent, a dissolution aid, a stabilizer, an isotonic agent, a preservative, an adsorption inhibitor, a surfactant, a diluent, an excipient, a pH adjuster, a pain-relieving agent, a buffer, a reducing agent, an antioxidant, etc., depending on the administration method or dosage form. Including the above-mentioned agents, pharmaceutically acceptable carriers and preparations suitable for the present invention are described in detail in the literature [Remington's Pharmaceutical Sciences, 19th ed., 1995].

[0051] For a cell therapy agent or pharmaceutical composition according to a specific example, a method that can be easily implemented by a person with basic knowledge in the technical field to which the present invention belongs can be formulated using a pharmaceutically acceptable carrier and / or excipient, so as to be manufactured in a unit volume form or built into a multi-volume container. In this case, the dosage form can be a solution, suspension or emulsion in an oil or aqueous medium, or a powder, granule, tablet or capsule form.

[0052] Furthermore, another aspect provides a support for tissue engineering in which a fibroblast assembly according to a specific example is loaded on a biodegradable polymer scaffold.

[0053] As described above, according to a specific example, fibroblasts can secrete epithelial cell growth factor, extracellular matrix or vascular endothelial growth factor, and thus can be transplanted to an individual in need thereof in a state of being loaded on a scaffold to promote skin regeneration or angiogenesis. The tissue engineering support can be a support in which a fibroblast assembly is loaded in a support manufactured by molding a biodegradable polymer.

[0054] The biodegradable polymer decomposes slowly and spontaneously in the body after a predetermined period of time, and may include polymers having one or more characteristics of biocompatibility, blood affinity, anti-calcification properties, cell nutrients, and the function of forming an intercellular matrix. The types of such biodegradable polymers are not particularly limited in the present invention, but representative examples include fibrin, collagen, gelatin, chitosan, alginate, hyaluronic acid, dextran, polylactic acid, polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), poly-ε-(caprolactone), polyanhydride, polyorthoester, polyvinyl alcohol, polyethylene glycol, polyurethane, polyacrylic acid, poly-N-isopropylacrylamide, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) copolymers, copolymers thereof, mixtures thereof, and the like. At this time, the content of the biodegradable polymer in the composite support can be 5 to 99% by weight according to the molding viewpoint of the support or the loading viewpoint of the cell assembly. The composite support can be manufactured by molding the biodegradable polymer according to the existing known methods, such as: salt leaching method (solvent-casting and particle-leaching technique), gas foaming method (gasforming technique), method of manufacturing polymer fibers into non-woven fabrics to manufacture polymer mesh (fiber extrusion and fabric forming process), phase separation method (thermally induced phase separation technique), emulsion freeze drying method (emulsion freeze drying method), high pressure gas expansion method (high pressure gas expansion), etc.

[0055] The support body formed and manufactured as described above delivers the loaded cell aggregate to the transplanted tissue, and can play a role in making the cells attach and grow three-dimensionally to form new tissue. At this time, in terms of the attachment and growth of cells on the composite support body, the pore size and structure of the support body may have an impact. In order to allow the nutrient solution to evenly penetrate into the interior of the support body and allow the cells to grow well, a structure in which the pores are interconnected may be provided. Moreover, in the support body, the pores may have an average diameter of 50 to 600 μm.

[0056] As still another aspect, a three-dimensional culture system for drug screening including the fibroblast aggregate according to one specific example is provided.

[0057] The three-dimensional fibroblast aggregate has an artificial cell morphology that simulates the in vivo environment, and can be effectively used in actual cell morphology and function research or therapeutic agents (for example, the skin disease or vascular disease). Therefore, the three-dimensional culture system for drug screening including the three-dimensional fibroblast aggregate can replace animal experiments in experiments such as disease therapeutic agent efficacy tests for pharmaceuticals or cosmetics, or inflammation and allergy tests.

[0058] As another aspect, an in vitro three-dimensional skin dermis model including a fibroblast aggregate cultured from fibroblasts is provided.

[0059] As another aspect, an in vitro model for screening drugs (eg, MMP inhibitors or agents that increase the expression or activity of intracellular collagen) comprising a fibroblast aggregate cultured from fibroblasts is provided.

[0060] As another form, a method for preparing an in vitro model for screening an in vitro three-dimensional skin dermis model or an MMP inhibitor or an agent for increasing the expression or activity of intracellular collagen is provided, which comprises the following steps: culturing fibroblasts in a liquid culture medium in a culture container to obtain a culture containing fibroblast clusters formed by the detachment of fibroblasts from the surface, wherein the culture container has a surface coated with a protein, the protein has an activity of binding to fibroblasts, and the protein having an activity of binding to the fibroblasts binds to the fibroblasts in a manner weaker than the binding between fibroblasts; and culturing the fibroblast clusters derived from the culture for at least 12 hours.

[0061] The contents of the fibroblast aggregate and the method for producing the same are the same as described above.

[0062] In a specific example, the present specification can provide a composition or model for drug screening comprising a fibroblast aggregate cultured from fibroblasts. The drug can be a skin aging improvement agent; a therapeutic agent for inflammatory diseases, arthritis or cancer. Therefore, for example, an in vitro three-dimensional skin dermis model comprising a fibroblast aggregate cultured from fibroblasts can be used to screen skin aging improvement agents; therapeutic agents for inflammatory diseases, arthritis or cancer.

[0063] In a specific example, the fibroblast aggregate may exhibit pathological characteristics based on skin aging. For example, for the fibroblast aggregate, the expression or activity of collagen may be in a reduced state, or the expression or activity of matrix metalloproteinase (matrix metalloproteinase: MMP) may be in an increased state. The fibroblast aggregate may additionally be in a state where the expression or activity of fibronectin is reduced, or in a state where the expression or activity of elastin is increased. In this specification, the reduction or increase of the expression or activity may mean the following: compared to normal cells, or compared to fibroblasts cultured in a two-dimensional manner, the expression or activity of the mentioned protein or gene is in a reduced or increased state. The collagen may include collagen types I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII or XIV. Moreover, the MMP may include any one or more of MMP 1 to 28.

[0064] As mentioned in the background art above, the reduction of collagen can cause the synthesis of fibrous components and the loss of water in the skin tissue, as well as changes in the stratum corneum. Moreover, the collagen can be decomposed by MMP. Therefore, the fibroblast assembly according to a specific example in which the expression or activity of collagen is reduced or the expression or activity of MMP is increased can be effectively used in screening for drugs for improving skin aging. For example, the drug for improving the skin aging may include drugs with skin moisturizing effect, increase in elasticity, reduction of wrinkles and antioxidant activity. Moreover, the MMP can decompose the extracellular matrix and promote tumor metastasis and progression accordingly, and the synthesis and decomposition of collagen based on this can play a role in cancer metastasis. Moreover, it is known that MMP is overexpressed under pathological conditions such as inflammatory diseases such as arthritis or cancers such as cancer metastasis, and MMP inhibitors targeting MMP are developed as therapeutic agents for the above diseases. Therefore, the fibroblast cell assembly according to a specific example in which the expression or activity of collagen is reduced or the expression or activity of MMP is increased can be used effectively in screening therapeutic agents for inflammatory diseases, arthritis or cancer. The inflammatory disease can be selected from the group consisting of the following diseases: dermatitis, conjunctivitis, peritonitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatic arthritis, periarthritis of shoulder, tendinitis, tenosynovitis, peritendinitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome, multiple sclerosis, acute and chronic inflammatory diseases. Moreover, the arthritis can be osteoarthritis or rheumatoid arthritis. The cancer therapeutic agent includes not only substances that inhibit the cell proliferation of cancer itself, but also substances for inhibiting the metastasis of cancer.

[0065] The culture of the fibroblasts to the fibroblast aggregate can be carried out by adhering the fibroblasts to a culture container with a hydrophobic surface and then culturing and differentiating. Specifically, if the fibroblasts are adhered and cultured in a culture container with a hydrophobic surface, as the density of the adhered fibroblasts increases, the fibroblasts detach from the culture container, thereby forming a fibroblast aggregate. In addition, for the culture, after culturing into a fibroblast aggregate, or after forming a fibroblast aggregate, it can be cultured for at least 12 hours, or at least 1 day, for example, it can be cultured for 12 hours to 15 days, 1 to 15 days, 3 to 10 days, 3 to 7 days, or 5 to 7 days. The culture medium suitable for the culture is a culture medium commonly used in the culture and / or differentiation of fibroblasts, as long as it contains serum or is serum-free, and it is not limited. For example, a culture medium with serum added in DMEM (Dulbeco's modified eagle medium), Ham's F12, and a mixture thereof can be used. The details of the above-mentioned method for forming a cell aggregate by culture will be described later.

[0066] The fibroblast aggregate cultured from the fibroblasts according to a specific example can simulate the environment in the body well because it is cultured three-dimensionally, and can be effectively used as an in vitro skin dermis model because it contains an extracellular matrix. In this specification, the term "skin dermis model" (which can be used interchangeably with artificial dermis (dermal equivalent)) can refer to a model that patterns the structure or shape of dermal tissue or dermis, and can refer to a model that is considered to clarify the interaction between cells in the dermis and the correlation with structure or morphology.

[0067] As another form, a method for screening substances that reduce the expression or activity of MMP is provided, comprising the following steps: treating the fibroblast aggregate or in vitro three-dimensional skin dermis model with a test substance; measuring the expression or activity level of MMP in the fibroblast aggregate or skin dermis model treated with the test substance; comparing the measured expression or activity level of MMP with that of an untreated control group; and selecting a substance that reduces the expression or activity of MMP relative to the control group.

[0068] As another form, a method for screening substances that increase the expression or activity of collagen is provided, comprising the following steps: treating the fibroblast aggregate or in vitro three-dimensional skin dermis model with the substance to be tested; measuring the level of collagen expression or activity in the fibroblast aggregate or skin dermis model treated with the substance to be tested; comparing the measured level of collagen expression or activity with that of an untreated control group; and screening substances that increase the expression or activity of collagen relative to the control group.

[0069] In the above screening method, the substance to be detected can be any one selected from the group consisting of the following substances: low molecular weight compounds, antibodies, antisense nucleotides, short interfering RNA, short hairpin RNA, nucleic acids, proteins, peptides, other extracts and natural products.

[0070] The step of treating the substance to be detected may include the following steps: contacting the fibroblast aggregate or the in vitro three-dimensional skin dermis model with the substance to be detected. The contact may include, for example, the following steps: injecting a solution containing a predetermined concentration of the substance to be detected into each well containing one or more fibroblast aggregates or the in vitro three-dimensional skin dermis model.

[0071] The expression or activity level of the MMP or collagen can be measured by any one method selected from the group consisting of the following methods: Reverse Transcription-Polymerase Chain Reaction (RT-PCR), enzyme immunoassay (ELISA), immunohistochemistry, Western Blotting, immunoprecipitation, immunofluorescence and flow cytometry (FACS). In addition, the expression or activity level of the MMP or collagen can include measuring the content of secreted MMP or collagen in the culture medium. The content of collagen in the culture medium can be measured by hydroxyproline detection.

[0072] The measured expression or activity level of the MMP is compared with the level of the untreated control group, so that the substance that causes the expression or activity of the MMP to decrease relative to the control group can be selected as an MMP expression or activity inhibitor substance or candidate substance. The substance or candidate substance that causes the expression or activity of the MMP to decrease can be a skin aging improvement agent or a cancer therapeutic agent. In addition, the measured expression or activity level of the collagen can be compared with the level of the untreated control group, so that the substance that increases the expression or activity of the collagen compared to the control group can be selected as a collagen expression or activity inhibitor substance or candidate substance. The substance or candidate substance that causes the expression or activity of the collagen to decrease can be a skin aging improvement agent or a cancer therapeutic agent.

[0073] In one specific example, for a fibroblast aggregate cultured from fibroblasts, the expression or activity of collagen is in a reduced state, or the expression or activity of MMP is in an increased state, so the fibroblast aggregate according to a specific example can be effectively used to screen substances related to the expression or activity of collagen or MMP.

[0074] In another specific example, the present invention includes a well plate having more than one well, wherein at least one drug screening device seeded with the fibroblast cell aggregate is provided in the well. The contents of the fibroblast cell aggregate are the same as described above.

[0075] In addition, a drug screening method is provided, comprising the following steps: injecting a solution containing a candidate substance into each well of the drug screening device; culturing a well plate containing wells injected with the candidate substance; collecting the fibroblast aggregate from the well plate, or recovering the culture fluid from the well plate; performing a test on the collected fibroblasts, or performing a test on the culture fluid. The candidate substances may be the same or different candidate substances. For the culture, a person skilled in the art may determine any culture time and temperature. The test may, for example, include: an MMP secretion test using ELISA by the culture fluid; or an immunoblotting method performed by the fibroblast aggregate; or an ECM secretion test using immunohistochemical staining.

[0076] Beneficial Effects

[0077] According to a fibroblast aggregate based on a morphology or a method for manufacturing the same, the following technical effects are achieved: a large number of three-dimensional fibroblast aggregates can be easily obtained in a culture container in a short period of time, and the three-dimensional fibroblast aggregates surrounded by an extracellular matrix can be used as a cell source and transplanted into a living body using an injection preparation in a manner without damaging the fibroblasts.

[0078] Another form of in vitro three-dimensional skin dermis model and a method for screening drugs using the same have the following technical effects: since it is composed of a three-dimensional cell aggregate, it can ideally mimic the in vivo environment of the skin, which has structural and functional complexity. Moreover, it can also screen extracellular matrix-related substances including MMP or collagen at high-throughput. BRIEF DESCRIPTION OF THE DRAWINGS

[0079] Figure 1 The figure schematically illustrates a process of producing a three-dimensional fibroblast aggregate according to one specific example.

[0080] Figure 2 This is a graph in which the cell adhesion rate of fibroblasts according to a specific example is quantified according to the amount of protein.

[0081] Figure 3 The figure shows a fluorescent staining photograph of the cell morphology of fibroblasts according to one specific example.

[0082] Figure 4 This is a graph showing the phosphorylation activity of FAK in fibroblasts according to one specific example.

[0083] Figure 5 This is a diagram showing a photograph of formation of a three-dimensional fibroblast aggregate according to one specific example.

[0084] Figure 6 This is a diagram showing a photograph of formation of a three-dimensional fibroblast aggregate according to one specific example.

[0085] Figure 7 The figure shows the H&E staining result of a three-dimensional fibroblast aggregation according to one specific example.

[0086] Figure 8 The figure shows the results of immunofluorescence staining of type I collagen in a three-dimensional fibroblast aggregate according to one specific example.

[0087] Fig. 9 This is a graph showing the amount of VEGF secreted by a three-dimensional fibroblast aggregate according to one specific example.

[0088] Fig.10 This is a photograph showing the formation process of a three-dimensional fibroblast aggregate according to one specific example observed under a microscope.

[0089] Fig.11 This is a graph showing the relative expression levels of extracellular matrix-related genes in a three-dimensional fibroblast aggregate according to one specific example.

[0090] Fig.12This is a graph showing the results of measuring the collagen content of a three-dimensional fibroblast aggregate according to one specific example using a hydroxyproline test.

[0091] Fig.13 This is a diagram showing the results of measuring the expression level of collagen type I in a three-dimensional fibroblast assembly according to a specific example by immunostaining.

[0092] Fig.14 This is a diagram showing the results of measuring the expression level of type I collagen in a three-dimensional fibroblast aggregate according to a specific example by immunoblotting.

[0093] Fig.15 This is a graph showing the expression and secretion levels of MMP 1 in a three-dimensional fibroblast aggregate according to one specific example.

[0094] Fig.16 This is a graph showing the amount of MMP1 secreted by cells after a three-dimensional fibroblast aggregate was treated with an MMP1 inhibitor according to one specific example.

[0095] Fig.17 This is a graph showing the amount of MMP1 secreted by two-dimensionally cultured fibroblasts that were irradiated with ultraviolet light to induce MMP1 overexpression and then treated with an MMP1 inhibitor.

[0096] Fig.18 The figure schematically illustrates a drug screening device including a three-dimensional fibroblast aggregate and a method for screening drugs using the device according to one specific example. DETAILED DESCRIPTION

[0097] Hereinafter, the embodiments of the present invention will be described in more detail. However, these embodiments are only used to exemplify the present invention, and the scope of the present invention is not limited to these embodiments.

[0098] Example 1: Formation of three-dimensional fibroblast aggregates and analysis of their characteristics

[0099] In this example, fibroblasts are cultured in a culture container having a surface coated with a protein having an activity of binding to fibroblasts, thereby forming a three-dimensional fibroblast aggregate.

[0100] Figure 1 The figure schematically shows the process of preparing a three-dimensional fibroblast aggregate according to one specific example.

[0101] refer to Figure 1The fibroblasts were seeded into a culture container coated with MBP-FGF2. Then, the fibroblasts were cultured and detached in a two-dimensional manner on the surface of the culture container, and the detached or separated two-dimensional fibroblast aggregates were continued to be cultured in a floating state in the culture container, thereby starting to form three-dimensional fibroblast aggregates after 1 day. The following fact was confirmed: the three-dimensional fibroblast aggregate formed according to a specific example has the function of secreting extracellular matrix and vascular endothelial growth factor (VEGF). The following is about Figure 1 The formation process of the three-dimensional fibroblast aggregate and the characteristic analysis method and results are described.

[0102] (1) Analysis of cell adhesion characteristics and morphological changes of fibroblasts after adhesion

[0103] In order to construct a culture method to induce the formation of three-dimensional fibroblast aggregates, the cell adhesion properties of fibroblasts, cell adhesion signals based on adhesion matrix and cell morphology were analyzed.

[0104] (1.1) Cell adhesion analysis of fibroblasts

[0105] Non-Tissue Culture Treated 96-well Plate (NTCP; the surface is hydrophobic due to polystyrene material; Falcon) was coated with ECM fibronectin (20 μg / ml), MBP (10 μg / ml), MBP-VEGF (10 μg / ml), MBP-HBD (100 μg / ml), and MBP-FGF2 (10 μg / ml) for 4 hours, and then washed 3 times with PBS. Then, it was sealed with 100 μg / ml BSA for 1 hour and washed 3 times with PBS. 5x10 cells were added to each well. 4 cells / cm 2 Fibroblasts were suspended in serum-free DMEM medium and then seeded into 96-well plates coated with proteins, and then lysed in 37°C medium for a given hour, and then the morphology of the cells was observed. The adherent cells were lysed using a cell lysis buffer, and then the protein was measured by means of a BCA (bicinchoninic acid) test to quantify the adherent cells.

[0106] Figure 2 This is a graph showing quantification of the cell adhesion rate of fibroblasts based on the amount of protein according to one specific example.

[0107] like Figure 2As shown, no cell adhesion occurred in NTCP coated with BSA, MBP, and MBP-VEGF. In addition, NTCP coated with MBP-FGF2 showed a lower adhesion rate than ECM-fibronectin bound to the integrin of the cell membrane one hour after cell seeding.

[0108] (1.2) Cell morphology analysis based on fibroblast adhesion matrix

[0109] In (1.1) of Example 1 above, in order to compare the cell morphology of fibroblasts cultured in NTCP coated with fibronectin and MBP-FGF2, the fibroblasts were stained with palloidin 30 minutes, 1 hour, and 4 hours after adhesion.

[0110] Figure 3 The figure shows a fluorescent staining photograph of the cell morphology of fibroblasts according to one specific example.

[0111] like Figure 3 As shown, it was confirmed that the fibroblasts adhered to MBP-FGF2 had less activated cytoskeleton than those adhered to fibronectin. This means that the cell adhesion activity mediated by integrin, a cell adhesion molecule present on the cell membrane, is limited in the fibroblasts adhered to MBP-FGF compared to those adhered to fibronectin.

[0112] (1.3) Analysis of cell adhesion signals based on fibroblast adhesion matrix

[0113] In (1.1) of Example 1, the phosphorylation of focal adhesion kinase (FAK) was measured to compare the cell adhesion signals of fibroblasts cultured in NTCP coated with fibronectin and MBP-FGF2, respectively. To measure the phosphorylation of FAK, immunoblotting analysis was performed using anti-phospho-FAK antibody (Cell signaling) on ​​fibroblasts 30 minutes, 1 hour, and 4 hours after adhesion.

[0114] Figure 4 This is a graph showing the phosphorylation activity of FAK in fibroblasts according to one specific example.

[0115] like Figure 4 As shown in the results, it was confirmed that the phosphorylation of FAK was not activated in fibroblasts adherent to MBP-FGF2 compared to fibroblasts adherent to fibronectin, which means that the cell adhesion activity mediated by integrin is low in fibroblasts adherent to MBP-FGF2.

[0116] (2) Formation of three-dimensional fibroblast aggregates

[0117] Based on the results of (1.1) to (1.3) of Example 1, a culture method for forming a three-dimensional fibroblast aggregate was constructed.

[0118] For fibroblasts, 0.5×10 4 Cells / cm 2 to 1.5×10 5 Cells / cm 2 The cells were seeded at a cell concentration of 1, 2, and 3 days, respectively, and then cultured in a static culture medium at 37°C. In the early stage of culture, the fibroblasts, which existed in the form of sheets, detached from the culture surface over time and began to exist in the form of cell bodies after 1 day, so they could be easily recovered with a pipette without enzyme treatment such as trypsin.

[0119] Figure 5 This is a diagram showing a photograph of formation of a three-dimensional fibroblast aggregate according to one specific example.

[0120] like Figure 5 As shown in the figure, it can be confirmed that when cultured using FGM, at 1.25×10 5 Cells / cm 2 At cell concentrations above 100 μg / mL, efficient three-dimensional fibroblast aggregate formation is induced. At lower cell concentrations, the distance between cells required for cell-cell interaction is not sufficiently close, so cell aggregates may not form well. Although cell aggregates are formed in non-FGM culture media, higher concentrations may be required than in FGM for cell aggregate formation.

[0121] Figure 6 This is a diagram showing a photograph of three-dimensional fibroblast aggregate formation according to one specific example.

[0122] like Figure 6 As shown, it was confirmed that three-dimensional spherical cell aggregates with a size of 400 to 1000 μm or more, which could be detected by the naked eye, were formed in the surface coated with MBP-FGF2, depending on the pore size.

[0123] (3) Analysis of secretory function of three-dimensional fibroblast aggregates

[0124] (3.1) Analysis of extracellular matrix (ECM) secretion function

[0125] In Example 1 (2), 1.25×10 5 cells / cm 2 The cells were seeded at a concentration of 100 μg / cm2 to form a three-dimensional cell aggregate, washed several times with PBS, and fixed with 4% paraformaldehyde at room temperature for 30 minutes. Then, they were dehydrated with various concentrations of ethanol (50-100%) and embedded in paraffin. The prepared paraffin blocks were cut with a thickness of 4 μm using an ultrathin slicer and fixed on a slide, and then H&E staining and immunological staining for fibronectin and collagen type 1 were performed. Fluorescent immunostaining was performed for collagen type 1 staining. In the above treatment, the prepared slides were first treated in BSA (4%) for 1 hour, then immersed in PBS containing a primary antibody and reacted overnight, then washed 3 times with PBS, and then reacted with a secondary antibody in a dark room for 1 hour. After additional nuclear staining with DAPI, analysis was performed using a confocal microscope. The control group was subjected to the same treatment without using a primary antibody and analyzed.

[0126] Figure 7 The figure shows the results of H&E staining of a three-dimensional fibroblast aggregate according to one specific example.

[0127] like Figure 7 As shown, it was confirmed that the fibroblasts treated at the same concentration in all wells formed cell aggregates after culturing for 1 day.

[0128] Figure 8 The figure shows the results of immunofluorescence staining of type I collagen in a three-dimensional fibroblast aggregate according to one specific example.

[0129] like Figure 8 As shown, it was confirmed that collagen was stained throughout the three-dimensional fibroblast aggregate, which indicated that a large amount of collagen was secreted when the cell aggregate was formed.

[0130] (3.2) Analysis of vascular endothelial growth factor (VEGF) secretion

[0131] In (2) of Example 1, 1.25×10 5 cells / cm 2 Cell concentration was seeded on 96-well NTCP coated with MBP-FGF2 to form three-dimensional cell aggregates and recovered to measure the secretion of vascular endothelial growth factor (VEGF).

[0132] Specifically, the formed three-dimensional cell aggregates were aggregated in units of 10 and transferred to 6-well NTCP, and then washed once with PBS. In addition, they were washed once with alpha MEM (Lonza) without FBS, and then alpha MEM (1.5 mL) was added and cultured in a static culture medium for 1 day. Then, the culture medium was collected every pre-set date and a new culture medium was added. The VEGF present in the collected culture medium was quantified using an ELISA kit (R&D). The kit was used according to the protocol of the supplier. Fig. 9 This is a graph showing the amount of VEGF secreted by a three-dimensional fibroblast aggregate according to one specific example.

[0133] Fig. 9 This is a graph showing the amount of VEGF secreted by a three-dimensional fibroblast aggregate according to one specific example.

[0134] like Fig. 9 As described above, it was found that the amount of VEGF in the three-dimensional fibroblast aggregate was more than two times higher than that in the cells cultured in a two-dimensional manner.

[0135] Example 2: Preparation of an in vitro three-dimensional artificial dermis model and analysis of its characteristics

[0136] (1) Fabrication of in vitro three-dimensional artificial dermis model

[0137] In order to make an in vitro three-dimensional artificial dermis model, fibroblasts were first cultured. Specifically, human dermal fibroblasts were cultured in a tissue culture round-bottom flask at 37°C, 5% CO2, and 95% O2 in high glucose Dulbecco's modified Eagle's medium (DMEM; Weljen; Daegu, South Korea). Human dermal fibroblasts at passage number 5 were used in all experiments.

[0138] Then, a culture container for three-dimensional culture of fibroblasts was prepared as follows. MBP (maltose binding protein)-FGF (fibroblast growth factor) (20 μg / ml) was coated at room temperature for 4 hours in a non-tissue cell culture 96-well plate (NTCP; formed of polystyrene material and having a hydrophobic surface; Falcon). Then, it was washed three times with PBS to remove the unbound MBP-FGF. The detailed manufacturing method of the culture container is described in Korean Patent Publication No. 10-2010-0122778, and the entire document is included in this specification as a reference.

[0139] The fibroblasts were seeded in the culture container to produce a three-dimensional fibroblast aggregate. Specifically, 1.25×10 5 cells / cm 2 Fibroblasts were seeded into the 96-well plate in fibroblast growth medium (FGM, Lonza) at a concentration of and cultured at 37°C. Fibroblasts were cultured and detached in a two-dimensional manner on the surface of the culture container, and the detached or separated two-dimensional fibroblast aggregates continued to be cultured in a floating state in the culture container, thereby spontaneously forming three-dimensional fibroblast aggregates within 24 hours. The formed three-dimensional fibroblast aggregates were collected on the first day (1day), the third day (3day) and the fifth day (5day) of culture, and the formation process of the three-dimensional fibroblast aggregates of adhesive fibroblasts was observed using a phase contrast microscope (Carl Zeiss; Germany), and the results are shown in Fig.10 Hereinafter, the three-dimensional fibroblast aggregate is referred to as “3DCM”.

[0140] Furthermore, as a comparative example, the fibroblasts were cultured in a two-dimensional manner. Specifically, 1.25×10 5 cells / cm 2 Adipose stem cells were then cultured in fibroblast growth medium (FGM, Lonza). In order to perform the same analysis of the characteristics of the artificial dermis model as the three-dimensional cell aggregate, cells were collected on the first day (1day), the third day (3day) and the fifth day (5day) of culture. Hereinafter, the cells cultured in two dimensions are represented as "2D".

[0141] Fig.10 This is a photograph showing the formation process of a three-dimensional fibroblast aggregate according to one specific example observed under a microscope.

[0142] like Fig.10 As shown, it was confirmed that a three-dimensional spherical cell aggregate with a size of 400 to 1000 μm or more, which was detectable with the naked eye, was formed.

[0143] (2) Characteristic analysis of in vitro three-dimensional artificial dermis model

[0144] In order to analyze the characteristics of the three-dimensional fibroblast assembly prepared as described above as an artificial dermis model, the following experiment was performed.

[0145] (2.1) Extracellular matrix (ECM) gene expression analysis in three-dimensional fibroblast aggregates

[0146] qRT-PCR (Quantitative Real-Time Polymerase Chain Reaction) was used to analyze the gene expression levels of collagen, fibronectin, and elastin, which are genes related to the extracellular matrix.

[0147] Specifically, total RNA was extracted from 3DCM and 2D at different times (first day, third day, and fifth day) using the Qiagen miniprep kit (Qiagen Inc; USA) according to the manufacturer's instructions. The extracted RNA was dissolved in nuclease-free water, and the RNA concentration was quantified using a NanoDrop ND1000 spectrophotometer (Thermo Fisher Scientific). Complementary DNA synthesis was performed using Maxime RT PreMix (iNtRon; South Korea) according to the manufacturer's instructions. All target primer sequences were purchased from Bioneer (South Korea). All polymerization chain reactions were performed using ABI Prism 7500 (Applied Biosystems), and gene expression levels were quantified using SYBR Premix Ex Taq (TaKaRa; Japan). Relative gene expression levels were calculated using the comparative Ct method, and the results are shown in Fig.11 .

[0148] Fig.11 This is a graph showing the relative expression levels of extracellular matrix-related genes in a three-dimensional fibroblast aggregate according to one specific example.

[0149] like Fig.11As shown, it can be confirmed that the expression levels of collagen type 1 and fibronectin in 3DCM are about 3 times lower than those in 2D, and for elastin, the expression level in 3DCM is increased compared to 2D. In particular, for elastin, the expression levels of 2D and 3DCM on the first day of culture are similar, but there is a significant increase from the third day of culture. Due to the above results, according to a specific example, the three-dimensional fibroblast aggregate simulates the environment of the skin dermis where the expression of collagen and fibronectin is reduced and the expression of elastin is increased, and it can be effectively used in the development of materials that use it as a target.

[0150] (2.2) Analysis of collagen expression in three-dimensional fibroblast aggregates

[0151] To analyze collagen in three-dimensional fibroblast aggregates, hydroxyproline assay, immunostaining and immunoblotting were performed.

[0152] Specifically, for the hydroxyproline assay, 2D, 3DCM (3×10 6 Cells) were hydrolyzed with 12N HCl solution at 120°C for 3 hours. The experiment was performed using a hydroxyproline reagent kit (Sigma-Aldrich) according to the manufacturer's instructions. The absorbance was measured at 560 nm using a Multisakn (Thermo), and the results are shown in Fig.12 .

[0153] For immunostaining, the 3DCM and 2D collected at different times were washed three times with PBS and fixed with 4% PFA for 30 minutes. Then, they were embedded in OCT compound (optimal cutting temperature compound) (TISSUE-TEK ¢c4583; Sakura Finetek USA, Inc.), frozen at -28°C, and cut at 6 μm thickness. To avoid nonspecific binding, the sections were incubated in BSA (4%) at room temperature for 1 hour. Then, they were incubated overnight at 4°C using a primary antibody against collagen I (Rabit, Abicam). Then, the samples were washed with PBS and incubated with the corresponding fluorescent-conjugated secondary antibody (Donkey anti-rabbit) (Life Technologies) in 1% BSA for 1 hour at room temperature. In addition, DAPI (4,5-diamino-2-phenylindole) (Vector Laboratories) was used for nuclear staining. The control group was performed under the same conditions without the primary antibody and observed using a confocal microscope (Carl Zeiss). The results are shown in Fig.13 .

[0154] For immunoblotting, cells cultured in the same manner as described above were solubilized with RIPA buffer (Sigma-Aldrich) together with protease inhibitor cocktail. The lysate was then centrifuged at 15,000 g for 30 minutes at 4°C, diluted to Laemmli medium containing 2% SDS and 5% (v / v) 2-mercaptoethanol, and heated at 90°C for 5 minutes. Proteins were separated by SDS-PAGE using 10% resolving gel and transferred to a nitrocellulose membrane (Bio-Rad; USA). The membrane was incubated overnight at 4°C with primary antibodies related to collagen type I (Collal, Boster Bio CO. Ltd) and β-actin (Santan Cruz Biotechnology). For detection, the membrane was incubated with peroxidase-conjugated antibody (SantaCruz Biotechnology) at room temperature for 1 hour. The chemiluminescent image was formed and scanned using an image analyzer (LSA3000, Fujifilm). The results are shown in Fig.14 .

[0155] Fig.12 This is a graph showing the results of measuring the collagen content of a three-dimensional fibroblast aggregate according to one specific example by a hydroxyproline test.

[0156] Fig.13This is a diagram showing the results of measuring the collagen expression level of fibroblast cell aggregates according to one specific example by immunostaining.

[0157] Fig.14 This is a diagram showing the results of measuring the collagen expression level of fibroblast cell aggregates according to one specific example by immunoblotting.

[0158] like Fig.12 As shown, it was confirmed that the total amount of collagen secreted by 3DCM increased as the culture time became longer, and it was confirmed that it decreased compared with 2D. It was found that the above results were consistent with the results of (2.1) of Example 2.

[0159] Moreover, if Fig.13 As shown, the staining of collagen type I decreased during the culture period in 3DCM, but did not decrease in 2D. The above results indicate that collagen type I is degraded during the culture period in a three-dimensional culture system.

[0160] And, if Fig.14 As shown, it can be confirmed that Fig.12 Consistent with the results, collagen type I fragmented during culture in 3DCM, whereas this was not the case in 2D.

[0161] Based on the above results, it was found that the expression of collagen in the three-dimensional fibroblast aggregate according to one specific example was reduced, and thus the aggregate could be effectively used in screening for a candidate substance that promotes an increase in the content of collagen.

[0162] (2.3) Analysis of MMP expression in three-dimensional fibroblast aggregates

[0163] RT-PCR was performed to analyze the expression of matrix metalloproteinase (MMP) 1 in three-dimensional fibroblast aggregates. RT-PCR was performed in the same manner as in (2.1) of Example 2, and the results are shown in Fig.15 a.

[0164] Furthermore, ELISA was performed to analyze the secretion of total MMP-1. Specifically, culture media were prepared from 2D and 3DCM at different times (day 1, day 3, and day 5). The test was performed using the Quantikine ELISA Human Total MMP 1 Kit (R&D System) according to the manufacturer's instructions. The absorbance was measured at 560 nm using a Multisakn (Thermo), and the results are shown in Fig.15 b.

[0165] Fig.15This is a graph showing the expression and secretion levels of MMP1 in a three-dimensional fibroblast aggregate according to one specific example.

[0166] like Fig.15 As shown, it can be confirmed that the expression level of MMP1 gene in 3DCM is significantly increased compared with 2D. In addition, as shown in ELISA analysis, the secretion level of MMP1 is also significantly increased in 3DCM compared with 2D. Based on the above results, it can be seen that the three-dimensional fibroblast aggregate according to one specific example is in a state where the expression of MMP is significantly increased, and therefore it can be effectively used in the development of substances that target it.

[0167] (3) Evaluation of the inhibitory function of MMP inhibitors using three-dimensional fibroblast aggregates

[0168] In this example, in order to additionally confirm whether the three-dimensional fibroblast aggregate can be used for screening of MMP inhibitors, currently known MMP inhibitors were treated to confirm the secretion amount of MMP.

[0169] Specifically, retinoic acid (10 mM), abietic acid (100 mM), and transforming growth factor-b1 (TGF-b1) (5 ng / ml) diluted in fibroblast growth media (Fibroblast Growth Media, FGM, Lonza) were inoculated into the three-dimensional fibroblast aggregates prepared in (1) of Example 2 on the first day of culture. Then, additionally, after being placed at 37°C for 2 and 4 days, they were cultured in a static culture medium, and the culture fluid was recovered to measure the secretion of matrix metalloproteinase-1 (MMP1). The measurement was quantified using an ELISA kit (R&D Company), and the method of use was carried out according to the supplier's protocol. The results are shown in Fig.16 .

[0170] As a control group of three-dimensional fibroblast aggregates, fibroblasts irradiated with ultraviolet B were used to compare the inhibitory function of MMP inhibitors in fibroblasts cultured in a two-dimensional manner. Specifically, 2.5×10 5 Cells / cm 2Cell concentration The suspended fibroblasts were seeded in a high-concentration glucose DMEM medium and then cultured in a static medium at 37°C for 1 day. Then, they were washed three times with PBS, added to a serum-free MEM medium, and cultured in a static medium at 37°C for 1 hour. In addition, they were washed three times with PBS and then irradiated with ultraviolet B (20 mJ / cm 2 ). After irradiation with ultraviolet light, various concentrations of retinoic acid (2, 10, 40 mM), abietic acid (20, 100, 400 mM), and TGF-b1 (1, 5, 20, ng / ml) diluted in fibroblast growth media (Fibroblast Growth Media, FGM, Lonza) were inoculated, and then cultured in static culture medium at 37°C for 2 days. The culture medium was then recovered to measure the amount of MMP1 secretion. The measurement was quantified using an ELISA kit (R&D Company) and the method of use was carried out according to the supplier's protocol. The results are shown in Fig.17 .

[0171] Fig.16 This is a graph showing the amount of MMP1 secreted by cells after a three-dimensional fibroblast aggregate was treated with an MMP1 inhibitor according to one specific example.

[0172] Fig.17 This is a graph showing the amount of MMP1 secreted by fibroblasts cultured two-dimensionally and irradiated with ultraviolet light to induce overexpression of MMP1, after which the cells were treated with an MMP1 inhibitor.

[0173] like Fig.16 As shown, for fibroblast aggregates not treated with MMP1 inhibitors, the secretion of MMP1 increased by 2.1 times and 2.4 times over the 2nd and 4th day of culture, respectively. On the contrary, for fibroblasts treated with retinoic acid and abietic acid, the secretion was about 80% and 81% of the control group, respectively, and the secretion of the group treated with TGF-b1 was about 60%.

[0174] like Fig.17As shown, fibroblasts irradiated with ultraviolet B in a two-dimensional culture showed an MMP1 secretion level that was about 1.3 times higher than that of unirradiated fibroblasts. However, the MMP1 secretion level of fibroblasts treated with retinoic acid was reduced by about 30% compared with the control group, and when compared with the TGF-b1 treated group, it was reduced by 25-35% depending on the treatment amount. In particular, for fibroblasts treated with abietic acid, the secretion level was reduced by about half when treated with 20mM, but when treated with 100mM or more, the secretion level was about 2% of the control group. Compared with the results evaluated by 3DCM, the tendency of secretion reduction when treated with inhibitors was the same. However, the reduction in the MMP inhibitor control group in 2D was 2.7 times higher in the retinoic acid treatment group, 1.7 to 2.4 times higher in TGF-b1, and 1.7 to 40 times higher in abietic acid compared with 3DCM.

[0175] Based on the above results, 2DCM is not suitable for drug screening because of its significantly high sensitivity of cells to drugs, and it is known that 3DCM can be effectively used in the screening of drugs including MMP inhibitors.

[0176] Fig.18 FIG. 1 is a diagram schematically showing a drug screening device including a three-dimensional fibroblast aggregate according to a specific example and a method for screening drugs using the device. Fig.18 A drug screening device is provided, comprising a well plate having one or more wells, wherein the wells are seeded with a three-dimensional fibroblast cell aggregate according to one or more specific examples. Each cell aggregate in the three-dimensional fibroblast cell aggregate may include 3.0×10 5 to 1.0×10 6 cells. Moreover, the diameter of the cell aggregate can be 300 to 2000 μm, and the shape can be spherical (including spheres) or sheet-like. The drug, i.e., the candidate substance, is as described above. A drug screening method is provided, comprising the following steps: injecting a solution containing a candidate substance into each well of the drug screening device; culturing a well plate containing the wells injected with the candidate substance; collecting the three-dimensional fibroblast aggregate from the well plate, or recovering the culture fluid from the well plate; performing the test by the collected fibroblasts, or performing the test by the culture fluid. The candidate substances may be the same or different candidate substances. Regarding the culture, those skilled in the art may arbitrarily determine the culture time and temperature. The test may, for example, include an MMP secretion test using ELISA by the culture fluid, or an ECM secretion test using an immunoblotting method or immunohistochemical staining by the three-dimensional fibroblast aggregate.

Claims

1. A method for producing a fibroblast aggregate, comprising the following steps: Fibroblasts are cultured in a liquid culture medium in a culture container having a surface coated with a protein, thereby obtaining a culture containing fibroblast aggregates formed by detachment of the fibroblasts from the surface, wherein The protein has an activity of binding to fibroblasts; and isolating fibroblast aggregates from the culture, wherein the protein having the activity of binding to the fibroblasts is a fibroblast growth factor, Among them, fibroblast growth factor binds to fibroblasts in a weaker way than the binding between proteins bound to integrins and fibroblasts. Wherein, when culturing the fibroblasts, 1.25×10 5 Cells / cm 2 Seed fibroblasts at the above cell concentration.

2. The method of claim 1, wherein: The protein is immobilized on the surface of the culture container by means of any one or a combination of substances selected from the group consisting of the following substances: Maltose binding proteins, hydrophobins and hydrophobic cell penetrating peptides.